Today: 5 July 2026
Browse Category

NASDAQ:ARVN 18 November 2025 - 17 June 2026

Pfizer trades up with Rigel’s Veppanu deal done

Pfizer trades up with Rigel’s Veppanu deal done

Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed. Dow sets a record, Pfizer edges higher as tech lags Pfizer finished at $26.04, up 0.15%. The S&P 500 slipped 0.57% and the Nasdaq lost 1.15%. The Dow gained 0.64% for a record close, lifted as money rotated out of tech stocks into other sectors.
17 June 2026
·····
Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week

Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week

Pfizer Inc. and Arvinas scored FDA approval for Veppanu, a breast cancer pill, adding a fresh weapon to Pfizer’s oncology lineup. With this nod, Pfizer gains ground in its push to prove it can replace waning sales from legacy products after the COVID boom. Pfizer’s upcoming first-quarter earnings, set for Tuesday, put a fresh spotlight on growth prospects, looming patent cliffs, and the payoff from its latest drug pipeline moves. Management fields analyst questions during a call slated for 10 a.m. EDT on May 5.
3 May 2026
··
Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas jumped in double digits on November 18, 2025 amid a focused pipeline reset, FDA momentum for vepdegestrant and attention at the Jefferies London Healthcare Conference. Arvinas shares are in rally mode this Tuesday. By mid‑afternoon U.S. trading, ARVN is up more than 14% on the day, with intraday prices hovering around the low‑$13 level and turnover far above normal. Quiver Quantitative+1
18 November 2025
··

Stock Market Today

  • Global Investors Return to India Stocks as AI Rally Slows
    July 4, 2026, 11:48 PM EDT. Global investors are showing fresh interest in Indian equities, one of this year's laggards, as the rupee steadies and Middle East tensions ease, which has helped push oil prices down. The NSE Nifty 50 Index brings less volatility than most emerging markets, and some see it as a haven while money chases the AI story in South Korea and Taiwan. But India's absence from the AI run is part of its appeal, with analysts calling it a hedge in emerging markets. Lower commodity prices, steady interest rates and a better outlook for the macro economy are lifting sentiment. With earnings season approaching, investors see less risk from inflation and steadier capital flows, raising the prospect for earnings upgrades.
Go toTop